

HIGH STAKES

The Economic Case for Every New Branded Drug Has to Be Proved.

BIOPHARMACEUTICAL VALUE DEMONSTRATION – SOURCES

Executive Order 14297 (May 2025):

<https://www.federalregister.gov/documents/2025/05/15/2025-08876/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients>

Proclamation 11020 (April 2026):

<https://www.govinfo.gov/content/pkg/FR-2026-04-09/pdf/2026-06956.pdf>

White House Council of Economic Advisers, Savings from Most-Favored-Nation Drug Pricing Policy (May 2026):

<https://www.whitehouse.gov/research/2026/05/savings-from-most-favored-nation-drug-pricing-policy/>

White House fact sheet, MFN manufacturer agreements (April 2026):

<https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-announces-deal-with-regeneron-to-bring-most-favored-nation-pricing-to-american-patients/>